Anticancer research · 2014
Risk factors for pericardial effusion in patients with stage I esophageal cancer treated with chemoradiotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tamari Keisuke, Isohashi Fumiaki, Akino Yuichi, Suzuki Osamu, Seo Yuji, Yoshioka Yasuo, Hayashi Yoshito, Nishida Tsutomu, Takehara Tetsuo, Mori Masaki, Doki Yuichiro, Ogawa Kazuhiko
Аннотация
AIM: We investigated clinical and dosimetric factors influencing the risk of developing pericardial effusion (PCE) in patients with Stage I esophageal cancer undergoing definitive chemoradiotherapy.
PATIENTS AND METHODS: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed.
RESULTS: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE.
CONCLUSION: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.
PATIENTS AND METHODS: Sixty-nine patients with Stage I esophageal cancer who underwent definitive chemoradiotherapy were retrospectively analyzed. Treatment comprised of three-dimensional conformal radiotherapy (60 Gy in 30 fractions) with concurrent chemotherapy. Clinical and dosimetric factors associated with PCE development were analyzed.
RESULTS: The median follow-up was 37 months (range=8-111 months); the crude PCE incidence rate was 52.2%. Grade 2 and 3 incidence rate was 47.8% and 4.3%, respectively. The median time to PCE onset was 5.7 months after radiotherapy. In multivariate analysis, pericardial V30 ≥ 41.6%, age ≥ 66 years, body mass index (BMI) ≥ 19 and diabetes mellitus (DM) were significant predictors of developing PCE.
CONCLUSION: The present study suggests that higher pericardial V30, advanced age, high BMI and DM are risk factors for developing PCE.